Agilent Technologies, Inc. (USD) Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.

Agilent Technologies, Inc. (USD) Active

5301 Stevens Creek Boulevard, Santa Clara, CA, US, 95051

Stock Price USD

Price Change

Last Dividend USD

A-

Latest Rating

A's stock peer is BDX (Becton, Dickinson and Company)

A's stock peer is CAH (Cardinal Health, Inc.)

A's stock peer is EW (Edwards Lifesciences Corporation)

A's stock peer is INSM (Insmed Incorporated)

A's stock peer is IQV (IQVIA Holdings Inc.)

A's stock peer is MTD (Mettler-Toledo International Inc.)

A's stock peer is WAT (Waters Corporation)

Healthcare Medical - Diagnostics & Research

Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.

80%

Dcf Rating

100%

Return On Equity

100%

Return On Assets

40%

Debt To Equity

40%

Price To Earnings

40%

Price To Book

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
2026-06-30	2026-07-22	0.26	0.74 %	Quarterly
2026-03-31	2026-04-22	0.26	0.88 %	Irregular
2026-01-06	2026-01-28	0.26	0.68 %	Quarterly
2025-09-30	2025-10-22	0.25	0.77 %	Quarterly
2025-07-01	2025-07-23	0.25	0.81 %	Quarterly
2025-04-01	2025-04-23	0.25	0.85 %	Quarterly
2024-12-31	2025-01-22	0.25	0.71 %	Quarterly
2024-10-01	2024-10-23	0.24	0.64 %	Irregular
2024-07-02	2024-07-24	0.24	0.74 %	Quarterly
2024-04-02	2024-04-24	0.24	0.63 %	Quarterly
2024-01-02	2024-01-24	0.24	0.66 %	Quarterly
2023-10-03	2023-10-25	0.23	0.81 %	Quarterly
2023-07-03	2023-07-26	0.23	0.74 %	Quarterly
2023-04-04	2023-04-26	0.23	0.63 %	Quarterly
2023-01-03	2023-01-25	0.23	0.57 %	Quarterly
2022-10-04	2022-10-26	0.21	0.66 %	Quarterly
2022-07-05	2022-07-27	0.21	0.69 %	Quarterly
2022-04-05	2022-04-27	0.21	0.60 %	Quarterly
2022-01-04	2022-01-26	0.21	0.51 %	Quarterly
2021-10-05	2021-10-27	0.19	0.51 %	Quarterly
2021-07-06	2021-07-28	0.19	0.51 %	Quarterly
2021-04-06	2021-04-28	0.19	0.58 %	Quarterly
2021-01-05	2021-01-27	0.19	0.62 %	Quarterly
2020-10-06	2020-10-28	0.18	0.70 %	Quarterly
2020-06-30	2020-07-22	0.18	0.81 %	Quarterly
2020-03-31	2020-04-22	0.18	0.95 %	Quarterly
2019-12-31	2020-01-22	0.18	0.79 %	Quarterly
2019-10-01	2019-10-23	0.16	0.86 %	Quarterly
2019-07-02	2019-07-24	0.16	0.85 %	Quarterly
2019-04-02	2019-04-24	0.16	0.77 %	Quarterly
2018-12-31	2019-01-23	0.16	0.93 %	Quarterly
2018-10-02	2018-10-24	0.15	0.84 %	Quarterly
2018-07-03	2018-07-25	0.15	0.94 %	Quarterly
2018-04-03	2018-04-25	0.15	0.87 %	Quarterly
2018-01-02	2018-01-24	0.15	0.81 %	Quarterly
2017-10-03	2017-10-25	0.13	0.81 %	Quarterly
2017-07-03	2017-07-26	0.13	0.87 %	Quarterly
2017-04-04	2017-04-26	0.13	0.93 %	Quarterly
2017-01-03	2017-01-25	0.13	1.05 %	Quarterly
2016-10-04	2016-10-26	0.12	0.98 %	Quarterly
2016-07-05	2016-07-27	0.12	1.00 %	Quarterly
2016-04-05	2016-04-27	0.12	1.07 %	Quarterly
2016-01-05	2016-01-27	0.12	0.99 %	Quarterly
2015-09-29	2015-10-21	0.10	1.16 %	Quarterly
2015-06-30	2015-07-22	0.10	0.99 %	Quarterly
2015-03-31	2015-04-22	0.10	0.95 %	Quarterly
2015-01-06	2015-01-28	0.10	0.94 %	Quarterly
2014-09-30	2014-10-22	0.13	0.93 %	Quarterly
2014-07-01	2014-07-23	0.13	0.90 %	Quarterly
2014-04-11	2014-04-23	0.13	0.91 %	Quarterly
2013-12-31	2014-01-22	0.13	0.86 %	Quarterly
2013-10-01	2013-10-23	0.12	0.89 %	Quarterly
2013-07-02	2013-07-24	0.12	1.03 %	Quarterly
2013-04-02	2013-04-24	0.12	1.00 %	Quarterly
2012-12-31	2013-01-23	0.10	0.98 %	Quarterly
2012-10-02	2012-10-24	0.10	0.78 %	Quarterly
2012-07-03	2012-07-25	0.10	0.51 %	Quarterly
2012-04-03	2012-04-25	0.10	0.22 %	Quarterly

Recent News

Excellere Partners and GHO Capital complete sale of Biocare Medical to Agilent Technologies

Denver, CO and London, UK – 25 June 2026: Excellere Partners (“Excellere”), a Denver-based private equity firm specializing in partnering with entrepreneurs and management teams, and GHO Capital Partners LLP (“GHO”), a specialist investor in global healthcare, today announced the completion of the sale of Biocare Medical ("Biocare"), a global leader in immunohistochemistry (IHC), in situ hybridization (ISH) and fluorescence in situ hybridization (FISH) solutions, to Agilent Technologies, Inc. ("Agilent", NYSE:A).

2026-06-25 08:06:00

Agilent Completes Acquisition of Biocare Medical

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the successful completion of its previously announced acquisition of Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP. Following the close of the transaction, Biocare is now part of Agilent's Life Sciences and Diagnostics Markets Group.“We are pleased to complete our acquisition of Biocare, which represents a natural and st.

2026-06-25 08:00:00

Lost Money on Verra Mobility Corporation (VRRM)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Alert: Claims Focus on Alleged Misrepresentations About the Durability of Verra Mobility's Largest Customer Contract and the $35 Million Revenue Hole Left by Avis Budget Group's Termination NEW YORK, June 24, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Verra Mobility Corporation (NASDAQ: VRRM) securities of a pending securities class action. THE CASE: A class action seeks to recover damages for investors who purchased VRRM securities between February 24, 2026 and May 26, 2026.

2026-06-24 10:09:00

Lost Money on Zoetis Inc. (ZTS)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Alert: Claims Focus on Alleged Misrepresentations About Weakening Veterinarian Adoption and Prescription Trends That Cost ZTS Investors $23.91 Per Share Following the Final Disclosure NEW YORK, June 24, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Zoetis Inc. (NYSE: ZTS) securities of a pending securities class action. THE CASE: A class action seeks to recover damages for investors who purchased Zoetis securities between January 14, 2025 and May 6, 2026.

2026-06-24 10:09:00

GPK Deadline Alert: Levi & Korsinsky Reminds Graphic Packaging Holding Company (GPK) Investors of Securities Class Action Deadline on July 6, 2026

Alert: Claims Focus on Alleged Inventory Mismanagement and Production Curtailments That Drove $130 Million in Projected 2026 EBITDA Losses NEW YORK, June 24, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Graphic Packaging Holding Company (NYSE: GPK) securities of a pending securities class action. THE CASE: A class action seeks to recover damages for investors who purchased GPK securities between February 4, 2025 and February 2, 2026.

2026-06-24 10:07:00

UMH PROPERTIES, INC. WELCOMES THE 21ST CENTURY ROAD TO HOUSING ACT: A MAJOR BOOST FOR AFFORDABLE MANUFACTURED HOUSING

Freehold, NJ, June 24, 2026 (GLOBE NEWSWIRE) -- UMH Properties, Inc. (NYSE: UMH) (TASE: UMH), a real estate investment trust (REIT) specializing in manufactured home communities, today expressed strong support for the 21st Century ROAD to Housing Act, comprehensive bipartisan legislation designed to address the nation's housing shortage by expanding supply, reducing costs, and modernizing regulations for manufactured housing.

2026-06-24 06:45:00

Tradeweb Announces Date for Second Quarter 2026 Financial Results

NEW YORK--(BUSINESS WIRE)--Tradeweb Markets Inc. (Nasdaq: TW), a global leader in electronic trading across asset classes, will release financial results for the second quarter of 2026 on Thursday, July 30, 2026, at approximately 7:00 AM EDT. In addition, Tradeweb will host a conference call for investors. WHO: Billy Hult, CEO Sara Furber, CFO Ashley Serrao, Head of Treasury, FP&A and IR WHAT: A discussion of financial results for the second quarter of 2026 followed by a question-and-answ.

2026-06-23 14:00:00

The Presidio Group Exclusively Advised Fletcher Jones Automotive Group on the Sale of Porsche, Mercedes-Benz and Audi dealerships in Northern California to AutoNation

FREMONT, Calif.--(BUSINESS WIRE)-- #Audi--The Presidio Group LLC (“Presidio”), an independent merchant banking firm focused on mergers and acquisitions, capital raising and investments in the automotive retail and consumer mobility sectors, exclusively advised Fletcher Jones Automotive Group (“Fletcher Jones”) on the sale of Fletcher Jones Motorcars (Mercedes-Benz) of Fremont, Audi Fremont and Porsche Fremont in Fremont, Calif., and their related real estate, to AutoNation Inc. (“AutoNation”) (“NYSE: A.

2026-06-23 10:20:00

MSFT Shareholder Alert: Microsoft Corporation Securities Class Action Lawsuit - Investors Should Contact SueWallSt

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- SueWallSt reminds purchasers of Microsoft Corporation (NASDAQ: MSFT) securities of a pending securities class action. THE CASE: A class action seeks to recover damages for investors who purchased Microsoft securities between May 1, 2025 and January 28, 2026.

2026-06-23 10:13:00

Lost Money on Erasca, Inc. (ERAS)? Join Class Action Suit Seeking Recovery - Contact SueWallSt

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- SueWallSt reminds purchasers of Erasca, Inc. (NASDAQ: ERAS) securities of a pending securities class action. THE CASE: A class action seeks to recover damages for investors who purchased ERAS securities between January 14, 2025 and April 26, 2026.

2026-06-23 10:09:00

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions